H A Nasrallah

Summary

Affiliation: University of Cincinnati
Country: USA

Publications

  1. ncbi Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia
    Elizabeth Gilday
    Department of Psychiatry and Behavioral Neuroscience, University of Cincimati, 260 Stetson Street, Suite 3200, Cincinnati, OH 45219, USA
    Rev Recent Clin Trials 7:2-9. 2012
  2. ncbi Improving patient outcomes in schizophrenia: achieving remission
    Henry A Nasrallah
    University of Cincinnati College of Medicine, Cincinnati, OH 45267 0599, USA
    J Psychopharmacol 20:57-61. 2006
  3. ncbi Defining and measuring clinical effectiveness in the treatment of schizophrenia
    Henry A Nasrallah
    Department of Psychiatry, University of Cincinnati Medical Center, Cincinnati, Ohio 45267 0559, USA
    Psychiatr Serv 56:273-82. 2005
  4. ncbi An overview of common medical comorbidities in patients with schizophrenia
    Henry A Nasrallah
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA
    J Clin Psychiatry 66:3-4. 2005
  5. ncbi Neurologic comorbidities in schizophrenia
    Henry A Nasrallah
    Department of Psychiatry, University of Cincinnati Medical Center, Cincinnati, Ohio 45267, USA
    J Clin Psychiatry 66:34-46. 2005
  6. ncbi Beyond the facts in schizophrenia: closing the gaps in diagnosis, pathophysiology, and treatment
    H Nasrallah
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45244, USA
    Epidemiol Psychiatr Sci 20:317-27. 2011
  7. ncbi Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
    H A Nasrallah
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH, USA
    Mol Psychiatry 13:27-35. 2008
  8. ncbi The case for long-acting antipsychotic agents in the post-CATIE era
    H A Nasrallah
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0599, USA
    Acta Psychiatr Scand 115:260-7. 2007
  9. ncbi The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial
    Henry A Nasrallah
    Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267 0559, USA
    J Clin Psychiatry 68:5-11. 2007
  10. ncbi Carbamazepine and valproate for the treatment of bipolar disorder: a review of the literature
    Henry A Nasrallah
    Department of Psychiatry, University of Cincinnati, Cincinnati, OH 45267 0559, USA
    J Affect Disord 95:69-78. 2006

Research Grants

  1. Schizophrenia Liability Genes among African-Americans
    Henry Nasrallah; Fiscal Year: 2002

Detail Information

Publications60

  1. ncbi Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia
    Elizabeth Gilday
    Department of Psychiatry and Behavioral Neuroscience, University of Cincimati, 260 Stetson Street, Suite 3200, Cincinnati, OH 45219, USA
    Rev Recent Clin Trials 7:2-9. 2012
    ..Current studies for clinical efficacy of paliperidone palmitate for both acute and maintenance treatment and adherence in adults with schizophrenia are discussed. Studies for safety and tolerability are also reviewed...
  2. ncbi Improving patient outcomes in schizophrenia: achieving remission
    Henry A Nasrallah
    University of Cincinnati College of Medicine, Cincinnati, OH 45267 0599, USA
    J Psychopharmacol 20:57-61. 2006
    ..Remission may, therefore, be considered as a current goal of treatment today, not a distant future aim...
  3. ncbi Defining and measuring clinical effectiveness in the treatment of schizophrenia
    Henry A Nasrallah
    Department of Psychiatry, University of Cincinnati Medical Center, Cincinnati, Ohio 45267 0559, USA
    Psychiatr Serv 56:273-82. 2005
    ..This report describes an approach to define and measure the clinical effectiveness of treatment in achieving these objectives...
  4. ncbi An overview of common medical comorbidities in patients with schizophrenia
    Henry A Nasrallah
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA
    J Clin Psychiatry 66:3-4. 2005
  5. ncbi Neurologic comorbidities in schizophrenia
    Henry A Nasrallah
    Department of Psychiatry, University of Cincinnati Medical Center, Cincinnati, Ohio 45267, USA
    J Clin Psychiatry 66:34-46. 2005
    ..Such recognition may permit earlier identification and treatment of schizophrenia, thus potentially improving long-term outcome...
  6. ncbi Beyond the facts in schizophrenia: closing the gaps in diagnosis, pathophysiology, and treatment
    H Nasrallah
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45244, USA
    Epidemiol Psychiatr Sci 20:317-27. 2011
    ....
  7. ncbi Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
    H A Nasrallah
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH, USA
    Mol Psychiatry 13:27-35. 2008
    ....
  8. ncbi The case for long-acting antipsychotic agents in the post-CATIE era
    H A Nasrallah
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0599, USA
    Acta Psychiatr Scand 115:260-7. 2007
    ..Long-acting antipsychotic agents were developed to promote treatment compliance in patients requiring maintenance treatment for schizophrenia...
  9. ncbi The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial
    Henry A Nasrallah
    Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267 0559, USA
    J Clin Psychiatry 68:5-11. 2007
    ..Except for clozapine, olanzapine clearly had the greatest metabolic side effect burden, and ziprasidone, the least. Perphenazine had the most motor side effects, although the rate was modest...
  10. ncbi Carbamazepine and valproate for the treatment of bipolar disorder: a review of the literature
    Henry A Nasrallah
    Department of Psychiatry, University of Cincinnati, Cincinnati, OH 45267 0559, USA
    J Affect Disord 95:69-78. 2006
    ..Controlled and direct comparative studies, both short and long term, are needed to further clarify the differences between VPA and CBZ...
  11. ncbi Metabolic findings from the CATIE trial and their relation to tolerability
    Henry A Nasrallah
    University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    CNS Spectr 11:32-9. 2006
    ..This article highlights the metabolic findings from the CATIE schizophrenia study, and explores the differences shown by atypical antipsychotics, with regard to metabolic side effects that increase cardiovascular risk...
  12. ncbi Introduction: evaluating the evidence: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and beyond
    Henry A Nasrallah
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0559, USA
    J Clin Psychiatry 68:3-4. 2007
  13. ncbi Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia
    Henry Nasrallah
    University of Cincinnati, Department of Psychiatry, Cincinnati, OH 45267 0559, USA
    Psychiatry Res 161:213-24. 2008
    ..Initial reliability and validity assessments suggest the PSP may be a useful measure of social functioning in patients with stable schizophrenia...
  14. ncbi Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care
    Henry A Nasrallah
    Department of Psychiatry, Neurology, and Neuroscience, University of Cincinnati Medical Center in Cincinnati, OH 45267 0559, USA
    J Clin Psychopharmacol 24:S7-14. 2004
    ..As clinicians refine practice patterns regarding the atypical antipsychotics, they may require additional knowledge and resources to fully incorporate risk/benefit considerations and optimize long-term psychiatric and medical outcomes...
  15. ncbi Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania
    Henry A Nasrallah
    University of Cincinnati College of Medicine, Cincinnati, OH, USA
    Bipolar Disord 8:467-74. 2006
    ..To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania...
  16. ncbi Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: preliminary analysis of retrospective data
    Henry A Nasrallah
    Department of Psychiatry, University of Cincinnati Medical Center, 231 Albert Sabin Way, Cincinnati, OH 45267 0559, USA
    Am J Geriatr Psychiatry 12:437-9. 2004
    ..The authors examined the mortality rate in geriatric patients receiving either haloperidol or atypical antipsychotics...
  17. ncbi Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone
    Henry A Nasrallah
    Department of Psychiatry, Neurology, and Neuroscience, University of Cincinnati Medical Center, 231 Albert Sabin Way, PO Box 670559, Cincinnati, OH 45267 0559, USA
    J Clin Psychiatry 65:531-6. 2004
    ..Results are discussed in the context of HRQoL in the general U.S. population...
  18. ncbi A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia
    Henry A Nasrallah
    Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267, USA
    Neuropsychopharmacology 35:2072-82. 2010
    ..All doses of once-monthly paliperidone palmitate were efficacious and generally tolerated, both locally and systemically. Paliperidone palmitate offers the potential to improve outcomes in adults with symptomatic schizophrenia...
  19. ncbi Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia
    Henry A Nasrallah
    Department of Psychiatry, University of Mississippi Medical Center, Jackson, Miss, USA
    J Clin Psychiatry 63:12-20. 2002
    ..This article will review the clinical trials examining the efficacy, safety, and tolerability of quetiapine in the treatment of patients with schizophrenia...
  20. ncbi Factors in antipsychotic drug selection: tolerability considerations
    Henry A Nasrallah
    University of Cincinnati Medical Center, Cincinnati, Ohio, USA
    CNS Spectr 8:23-5. 2003
    ..Regulatory agencies in some countries have already taken action in this regard...
  21. ncbi Iatrogenic disorders associated with conventional vs. atypical antipsychotics
    H A Nasrallah
    Department of Psychiatry, University of Mississippi School of Medicine, Jackson, USA
    Ann Clin Psychiatry 13:215-27. 2001
    ..Differences in tolerability among the new antipsychotics are described...
  22. ncbi Protection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindole
    H G Shertzer
    Department of Environmental Health and Center for Environmental Genetics, University of Cincinnati Medical Center, Cincinnati, OH 45267 0056, USA
    Int J Obes (Lond) 34:970-9. 2010
    ..Therefore, we examined the ability of APAP and THII to prevent metabolic changes in mice receiving OLZ...
  23. ncbi Paliperidone: a new extended-release oral atypical antipsychotic
    Heather Dlugosz
    University of Cincinnati, Department of Psychiatry, College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267 0559, USA
    Expert Opin Pharmacother 8:2307-13. 2007
    ..At present, there are no published data from a comparative trial with paliperidone ER versus its parent compound or other second-generation antipsychotic agents...
  24. ncbi Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego, USA
    Schizophr Res 101:273-86. 2008
    ..Given concerns over antipsychotic metabolic effects, this analysis explored MS status and outcomes in phase 1 of the CATIE Schizophrenia Trial...
  25. ncbi Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline
    Henry A Nasrallah
    University of Cincinnati, Cincinnati, OH 45267 0559, USA
    Schizophr Res 86:15-22. 2006
    ....
  26. ncbi Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of Schizophrenia
    Henry A Nasrallah
    Department of Psychiatry, University of Cincinnati College of Medicine, 260 Stetson St, Suite 3224, Cincinnati, OH 45267 0559, USA
    J Clin Psychiatry 70:4-46. 2009
    ..Summit faculty member opinion is compared with field survey results, and recommendations are made for future research...
  27. ncbi Neurological disorders in schizophrenia
    Arman Danielyan
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45244, USA
    Psychiatr Clin North Am 32:719-57. 2009
    ..In this article the most recent findings from multiple studies on neurological disorders in SZ are reviewed, and the authors make a strong argument for a neurological basis of the schizophrenic process...
  28. ncbi Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future
    Rajiv Tandon
    University of Florida, Department of Psychiatry, FL, USA
    Schizophr Res 122:1-23. 2010
    ..We evaluate the potential contribution of pharmacogenomics and other biological markers in optimizing individual treatment and outcome in the future...
  29. ncbi Temporal sequence of clinical manifestation in schizophrenia with co-morbid OCD: review and meta-analysis
    Kavi K Devulapalli
    Department of Epidemiology and Biostatistics, Case Western Reserve University School of Medicine, Cleveland, OH, USA
    Psychiatry Res 161:105-8. 2008
    ..A strong trend in the data exists suggesting that the onset of OCD precedes SCZ. Future prospective studies with larger sample sizes are warranted...
  30. ncbi Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study
    Jonathan M Meyer
    Department of Psychiatry, University of California at San Diego, USA
    Biol Psychiatry 66:1013-22. 2009
    ..Despite the known CV effects of atypical antipsychotics, there is limited prospective data on IM changes during treatment...
  31. ncbi Schizophrenia, "just the facts" 4. Clinical features and conceptualization
    Rajiv Tandon
    Department of Psychiatry, University of Florida College of Medicine, P O Box 100256, Gainesville, FL 32610, USA
    Schizophr Res 110:1-23. 2009
    ..Possible implications for DSM-V and ICD-11 definitions of schizophrenia are discussed...
  32. ncbi Focus on lower risk of tardive dyskinesia with atypical antipsychotics
    Henry A Nasrallah
    Departments of Psychiatry, Neurology, and Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA
    Ann Clin Psychiatry 18:57-62. 2006
    ....
  33. ncbi The urgent need for monitoring and intervention to reduce metabolic risk factors in patients with schizophrenia
    Henry A Nasrallah
    University of Cincinnati College of Medicine, Cincinnati, OH, USA
    CNS Spectr 13:5-6. 2008
  34. ncbi Raising the bar for treatment expectations in schizophrenia: achieving remission as a routine goal of antipsychotic pharmacotherapy
    Henry A Nasrallah
    J Psychopharmacol 20:3-5. 2006
  35. ncbi Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego, VA San Diego Healthcare System, San Diego, CA 92161, United States
    Schizophr Res 103:104-9. 2008
    ..Given concerns over antipsychotic effects on serum TG, this analysis explored changes in nonfasting TG in phase 1 of the CATIE Schizophrenia Trial...
  36. ncbi The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome
    Jonathan M Meyer
    VA San Diego Healthcare System, USA
    Schizophr Res 80:9-18. 2005
    ....
  37. ncbi Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder
    Robert Lasser
    Janssen Pharmaceutical Products, LP, Titusville, NJ, USA
    J Affect Disord 83:263-75. 2004
    ....
  38. ncbi The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists
    John W Newcomer
    Department of Psychiatry and Psychology, Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Psychopharmacol 24:S1-6. 2004
    ..The impact of additional data and educational efforts in this area, such as a recently published consensus statement from the American Diabetes Association and other organizations, remains to be assessed...
  39. ncbi Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics
    Samuel J Keith
    J Clin Psychiatry 65:120-31. 2004
  40. ncbi Risperidone in the treatment of delirium: results from a prospective open-label trial
    Dinesh Mittal
    Department of Veterans Affairs Medical Center, Jackson, Mississippi 39216, USA
    J Clin Psychiatry 65:662-7. 2004
    ..Effective treatment is necessary to reverse delirium and prevent potentially serious consequences...
  41. ncbi Schizophrenia and aging: no more dearth of data?
    Dilip V Jeste
    Am J Geriatr Psychiatry 11:584-7. 2003
  42. ncbi Treatment of bipolar disorder
    Hans Jurgen Moller
    Psychiatric Department of University Munich, Munich, Germany
    J Clin Psychiatry 64:9-17; discussion 28. 2003
    ..This article provides an overview of current management strategies for patients with bipolar disorder and describes how these approaches can be incorporated into clinical practice...
  43. ncbi Pharmacoeconomic implications of adverse effects during antipsychotic drug therapy
    Henry A Nasrallah
    University of Mississippi Medical Center, Veterans Affairs Medical Center, Jackson, MS, USA
    Am J Health Syst Pharm 59:S16-21. 2002
    ..A comprehensive evaluation of risk factors, outcomes, and costs should be include in economic evaluations of antipsychotic drugs so that realistic strategies for reducing costs and improving health can be identified...
  44. ncbi Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database
    Frank D Gianfrancesco
    HECON Associates, Montgomery Village, MD 20886, USA
    J Clin Psychiatry 63:920-30. 2002
    ..Case series suggest that some antipsychotics may induce or exacerbate type 2 diabetes. This study measured the association of antipsychotic treatments with diabetes at a population level...
  45. ncbi Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III
    Joseph P McEvoy
    Department of Psychiatry and Behavioral Sciences, Duke University, Clinical Research, John Umstead Hospital, 1003 12th Street, Butner, NC 27509, USA
    Schizophr Res 80:19-32. 2005
    ..One important risk factor for cardiovascular disease is the metabolic syndrome (MS), yet limited data exist on its prevalence in US patients with schizophrenia...
  46. ncbi Subjecting meta-analyses to closer scrutiny: Little support for differential efficacy among second-generation antipsychotics at equivalent doses
    Rajiv Tandon
    Arch Gen Psychiatry 63:935-7; author reply 937-9. 2006
  47. ncbi Pain insensitivity in schizophrenia: trait or state marker?
    Manpreet K Singh
    University of Cincinnati College of Medicine and Cincinnati Children's Hospital Medical Center, 45267, USA
    J Psychiatr Pract 12:90-102. 2006
    ..Future studies are needed to further clarify the neurobiology, pathophysiology, and practical clinical implications of this phenomenon...
  48. ncbi Strategies for maximizing clinical effectiveness in the treatment of schizophrenia
    Rajiv Tandon
    Florida Department of Children and Families, Tallahassee, FL 32399, USA
    J Psychiatr Pract 12:348-63. 2006
    ..Finally, the effectiveness of providing optimal individualized treatment/rehabilitation is best gauged by measuring progress on multiple effectiveness domains. Approaches for efficient and reliable assessment are discussed...
  49. ncbi Memantine normalizes brain activity in the inferior frontal gyrus: a controlled pilot fMRI study
    Michael A Cerullo
    Schizophr Res 97:294-6. 2007
  50. ncbi The influence of study design on the results of pharmacoepidemiologic studies of diabetes risk with antipsychotic therapy
    Frank Gianfrancesco
    HECON Associates, Inc, Montgomery Village, MD, USA
    Ann Clin Psychiatry 18:9-17. 2006
    ..Retrospective large patient database studies have reported conflicting findings regarding diabetes risks associated with antipsychotics. This study compared two study designs to assess antipsychotic-related diabetes risk...
  51. ncbi Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorder
    Terence A Ketter
    Stanford University School of Medicine, Stanford, CA 94305, USA
    Psychopharmacol Bull 39:120-46. 2006
    ..Further investigation of combinations of agents such as mood stabilizers and atypical antipsychotics may yield valuable insights into the potential of combination therapies to enhance clinical outcomes in patients with bipolar disorder...
  52. ncbi A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls
    Donald C Goff
    Massachusetts General Hospital, Harvard Medical School, Department of Psychiatry 25 Staniford Street, Boston, MA 02114, USA
    Schizophr Res 80:45-53. 2005
    ..The incidence of coronary heart disease (CHD) and the relative contribution of CHD to increased mortality in schizophrenia patients are not clear, despite recent concerns about metabolic complications of certain atypical antipsychotics...
  53. ncbi Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies
    Krishnan Ramaswamy
    Janssen Pharmaceutica Products, LP, Titusville, New Jersey, USA
    Ann Clin Psychiatry 18:183-94. 2006
    ....
  54. ncbi Antipsychotic-induced type 2 diabetes: evidence from a large health plan database
    Frank Gianfrancesco
    HECON Associates, 9833 Whetstone Drive, Montgomery Village, MD 20886, USA
    J Clin Psychopharmacol 23:328-35. 2003
    ..This study supports earlier findings on risperidone versus olanzapine and builds evidence on quetiapine. Additional studies are needed to evaluate the association of antipsychotic treatment with type 2 diabetes...
  55. ncbi Schizophrenia, "Just the Facts": what we know in 2008 part 1: overview
    Rajiv Tandon
    University of Florida, 3706 Glin Circle, Tallahassee, FL 32309, United States
    Schizophr Res 100:4-19. 2008
    ..We intend to follow this paper with the submission to the journal of a series of topic-specific articles, critically reviewing the evidence...
  56. ncbi Time-dependent effects of haloperidol and ziprasidone on nerve growth factor, cholinergic neurons, and spatial learning in rats
    Alvin V Terry
    Department of Pharmacology and Toxicology, CB 3618, Medical College of Georgia, 1120 Fifteenth St, Augusta, GA 30912 2450, USA
    J Pharmacol Exp Ther 318:709-24. 2006
    ..e., important neurobiological substrates of memory), and cognitive function...
  57. ncbi Improving the pedagogy associated with the teaching of psychopharmacology
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
    Acad Psychiatry 31:211-7. 2007
    ..The focus was on whether "improving the teaching-learning process" in psychiatric residency programs could improve clinical practice...
  58. ncbi Elevating the standard of care in the management of cardiometabolic risk factors in patients with mental illness. Conclusion: summary and recommendations
    John W Newcomer
    Center for Clinical Studies, Washington University School of Medicine, St. Louis, MO, USA
    CNS Spectr 13:13-4. 2008
  59. ncbi Celebrating twenty years of schizophrenia research
    Lynn E DeLisi
    Schizophr Res 100:1-3. 2008
  60. ncbi Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology
    Rajiv Tandon
    University of Florida, 3706 Glin Circle, Tallahassee, FL 32309, United States
    Schizophr Res 102:1-18. 2008
    ..The ability to question some of our basic assumptions about the etiology and nature of schizophrenia and greater rigor in its study appear critical to improving our understanding about its causation...

Research Grants1

  1. Schizophrenia Liability Genes among African-Americans
    Henry Nasrallah; Fiscal Year: 2002
    ..Finally, we have an outstanding track record of African American participation in research studies, and a deep appreciation of their population genetics. ..